Articles From: PharmAthene Fulfills Valortim® IDIQ Contract to Philip Morris International Inc. (PMI) Reports 2014 Third-Quarter Results; Revises 2014 Full-Year Reported Diluted EPS Forecast to a Range of $4.76 to $4.81 Reflecting Currency


ANNAPOLIS, Md.
Sign-up for PharmAthene Fulfills Valortim® IDIQ Contract investment picks
2014/11/6
ANNAPOLIS, Md.
Sign-up for PharmAthene Provides Third Quarter 2014 Operational And Financial Update investment picks
PharMerica Corporation (NYSE:PMC), a national provider of institutional, specialty home infusion, hospital and oncology pharmacy services, today announced that it has completed the acquisition of Millennium Pharmacy Systems (“Millennium”). Millennium is a pharmacy services provider to the long-term care industry that operates seven institutional pharmacies primarily in the Mid-Atlantic region.
Sign-up for PharMerica Acquires Millennium Pharmacy Systems investment picks
PharMerica Corporation (NYSE:PMC), a national provider of institutional, specialty home infusion, hospital and oncology pharmacy services, today announced that it has successfully closed on a new credit agreement.
Sign-up for PharMerica Announces New Senior Secured Credit Agreement investment picks
PharMerica Corporation (NYSE:PMC) announced today that it will provide an online webcast of its third quarter 2014 earnings conference call on Thursday, November 6, 2014.
Sign-up for PharMerica Corporation Announces Third Quarter 2014 Earnings Call and Webcast investment picks
PharMerica Corporation (NYSE:PMC), a national provider of institutional, specialty home infusion, hospital and oncology pharmacy services, today reported its financial results for the third quarter and nine months ended September 30, 2014.
Sign-up for PharMerica Reports Third Quarter 2014 Results investment picks
PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy, specialty home infusion, and oncology pharmacy services, today announced that David Froesel, Executive Vice President, Chief Financial Officer and Treasurer, will make a presentation regarding the Company at the Credit Suisse 2014 Healthcare Conference in Phoenix, Arizona, on Tuesday, November 11, 2014, at 1:30 p.m. Mountain Time (3:30 p.m. Eastern Time). The Company also announced that a live broadcast of its conference presentation, as well as any written materials accompanying the presentation, will be available on the “For Investors” tab of the Company’s website, www.pharmerica.com , under “Webcasts and Presentations.” In addition, the webcast, transcript and written materials will be archived on the Company’s website following the event.
Sign-up for PharMerica to Present at the Credit Suisse 2014 Healthcare Conference investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced results from the Phase 1 dose escalation study of the investigational EZH2 inhibitor EPZ-6438 (referred to as E7438 by Eisai) administered orally as a single agent in patients with advanced solid tumors and B-cell non-Hodgkin lymphomas.
Sign-up for Phase 1 Dose Escalation Data for Epizyme EZH2 Inhibitor EPZ-6438 (E7438) Shows Single Agent Activity in B-Cell Non-Hodgkin Lymphomas and Malignant Rhabdoid Tumor investment picks
-Trial Data Show 1404 More Sensitive Than MRI in Detecting Primary and Metastatic Prostate Cancer- TARRYTOWN, N.Y., Oct.
Sign-up for Phase 2 Data for Progenics' 1404 Imaging Agent Presented at EANM Congress investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today announced results from CheckMate -063, a Phase 2 single-arm, open-label study of Opdivo (nivolumab), an investigational PD-1 immune checkpoint inhibitor, administered as a single agent in patients with advanced squamous cell non-small cell lung cancer (NSCLC) who have progressed after at least two prior systemic treatments with 65% receiving three or more prior therapies (n=117). With approximately 11 months of minimum follow up, the objective response rate (ORR, the study’s primary endpoint) was 15% (95% CI = 8.7, 22.2) as assessed by an independent review committee (IRC) using RECIST 1.1 criteria and the median duration of response was not reached.
Sign-up for Phase 2 Objective Response Rate and Survival Data for Opdivo (nivolumab) in Heavily Pre-treated Advanced Squamous Cell Non-Small Cell Lung Cancer to be Presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology investment picks
- Median overall survival is encouraging for this patient population - - Most frequently observed adverse events consistent with MEK inhibitor class - BOULDER, Colo.
Sign-up for Phase 2 Trial Of Binimetinib In NRAS Melanoma Shows Promising Clinical Activity investment picks
- Data Presented Today as Late-Breaker at European Society for Medical Oncology (ESMO) 2014 Congress in Madrid - WEST LAFAYETTE, Ind., Sept.
Sign-up for Phase 2b TARGET Trial Results Show Improved Survival in Adenocarcinoma Non-Small Cell Lung Cancer Patients Treated With Endocyte's Vintafolide investment picks
http://media.marketwire.com/attachments/201203/41309_medivation_logo.jpg http://media.marketwire.com/attachments/201412/82607_astellas.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1164311&ProfileId=051205&sourceType=1 SAN FRANCISCO, CA and TOKYO, JAPAN --
Sign-up for Phase 3 PREVAIL Trial Named Clinical Advance of the Year by SCRIP investment picks
Pfizer Inc. (NYSE:PFE) announced today the publication of results from the PROFILE 1014 study in the December 4 issue of The New England Journal of Medicine .
Sign-up for Phase 3 Results Published in The New England Journal of Medicine Show Superiority of Pfizer’s XALKORI® (crizotinib) Compared to Platinum-Based Chemotherapy in Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today announced late-breaking data from the UNITY Trial program investigating a 12-week regimen of its all-oral daclatasvir (DCV) TRIO regimen – a fixed-dose combination of daclatasvir with asunaprevir (ASV) and beclabuvir (BCV) – in a broad range of patients with genotype 1 hepatitis C virus (HCV). The data will be presented at The Liver Meeting ® 2014, the Annual Meeting of The American Association for the Study of Liver Diseases (AASLD), in Boston, MA, November 7 – 11.
Sign-up for Phase 3 UNITY Trials Demonstrate High Cure Rates for Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination in Genotype 1 Hepatitis C Patients, Including Those with Cirrhosis investment picks
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that results from a double-blind, placebo-controlled, multicenter phase II trial of GED-0301 in 166 patients with active Crohn's disease will be presented at the United European Gastroenterology Week in Vienna, Austria.
Sign-up for Phase II Data in Crohn’s Disease for Celgene’s Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014 investment picks
PHH Corporation (NYSE: PHH) (“PHH” or the “Company”) today announced financial results for the quarter ended September 30, 2014.
Sign-up for PHH Corporation Announces Third Quarter 2014 Results investment picks
2014/11/7
PHI, Inc. (The Nasdaq Global Market: PHII (voting) PHIIK (non-voting)) today reported financial results for the quarter ended September 30, 2014.
Sign-up for PHI, Inc. Announces Results for the Third Quarter Ended September 30, 2014 investment picks
TEANECK, N.J., Nov.
Sign-up for Phibro Animal Health Corporation Declares Quarterly Dividend investment picks
TEANECK, N.J., Nov.
Sign-up for Phibro Animal Health Corporation Reports First Quarter investment picks
TEANECK, N.J., Sept.
Sign-up for Phibro Animal Health Corporation Reports Fourth Quarter and Annual Results investment picks
2014/12/9
(FROM THE WALL STREET JOURNAL 12/10/14) By Christian Berthelsen Phibro Trading LLC is closing its doors in the U.S., marking the end of an era for a commodities firm that came to prominence under oil trader Andrew Hall.
Sign-up for Phibro To Shut US Business investment picks
2014/10/24
The Philadelphia 76ers today announced the extension of their wide-ranging partnership with StubHub, the Official Fan-to-Fan Ticket Marketplace of the Philadelphia 76ers.
Sign-up for Philadelphia 76ers Extend Wide-Ranging Partnership With StubHub investment picks
2014/12/10
By Peter Loftus Philadelphia's transit agency has sued Gilead Sciences Inc., accusing the company of "price-gouging" on the sale of its $1,000-per-pill hepatitis C drug Sovaldi, the latest salvo in a battle between health-care payers and the pharmaceutical industry over prices.
Sign-up for Philadelphia Agency Sues Gilead Over Price Of Hepatitis Drug--Update investment picks
2014/12/10
By Peter Loftus Philadelphia's transit agency filed a lawsuit against Gilead Sciences Inc., accusing the company of price-gouging on the sale of its $1,000-per-pill hepatitis C drug Sovaldi, the latest salvo in a battle between some health-care payers and the pharmaceutical industry over prices.
Sign-up for Philadelphia Transit Agency Sues Gilead, Claiming Sovaldi Price-Gouging investment picks
Subsidiaries of Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today obtained a green light from an English Court to challenge the EU’s Tobacco Products Directive (2014/40/EU) before the Court of Justice of the European Union (CJEU). Key questions regarding the Directive’s validity will be referred to the CJEU as ordered by Mr.
Sign-up for Philip Morris International Granted Right to Challenge EU’s Tobacco Products Directive Before the Court of Justice of the European Union investment picks
2014/10/16
Regulatory News: Third-Quarter 2014 Reported diluted earnings per share of $1.38, down by $0.06 or 4.2% versus $1.44 in 2013 Excluding unfavorable currency of $0.20, reported diluted earnings per share up by $0.14 or 9.7% versus $1.44 in 2013 as detailed in the attached Schedule 13 Adjusted diluted earnings per share of $1.39, down by $0.05 or 3.5% versus $1.44 in 2013 Excluding unfavorable currency of $0.20, adjusted diluted earnings per share up by $0.15 or 10.4% versus $1.44 in 2013 as detailed in the attached Schedule 12 Cigarette shipment volume of 222.3 billion units, down by 0.4% excluding acquisitions Reported
Sign-up for Philip Morris International Inc. (PMI) Reports 2014 Third-Quarter Results; Revises 2014 Full-Year Reported Diluted EPS Forecast to a Range of $4.76 to $4.81 Reflecting Currency investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: PharmAthene Fulfills Valortim® IDIQ Contract to Philip Morris International Inc. (PMI) Reports 2014 Third-Quarter Results; Revises 2014 Full-Year Reported Diluted EPS Forecast to a Range of $4.76 to $4.81 Reflecting Currency
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent